Anti‐IL‐5 therapies for asthma

HA Farne, A Wilson, S Milan, E Banchoff… - Cochrane Database …, 2022 - cochranelibrary.com
HA Farne, A Wilson, S Milan, E Banchoff, F Yang, CVE Powell
Cochrane Database of Systematic Reviews, 2022cochranelibrary.com
Background This is the second update of previously published reviews in the Cochrane
Library (2015, first update 2017). Interleukin‐5 (IL‐5) is the main cytokine involved in the
proliferation, maturation, activation and survival of eosinophils, which cause airway
inflammation and are a classic feature of asthma. Studies of monoclonal antibodies targeting
IL‐5 or its receptor (IL‐5R) suggest they reduce asthma exacerbations, improve health‐
related quality of life (HRQoL) and lung function in appropriately selected patients, justifying …
Background
This is the second update of previously published reviews in the Cochrane Library (2015, first update 2017). Interleukin‐5 (IL‐5) is the main cytokine involved in the proliferation, maturation, activation and survival of eosinophils, which cause airway inflammation and are a classic feature of asthma. Studies of monoclonal antibodies targeting IL‐5 or its receptor (IL‐5R) suggest they reduce asthma exacerbations, improve health‐related quality of life (HRQoL) and lung function in appropriately selected patients, justifying their inclusion in the latest guidelines.
Objectives
To compare the effects of therapies targeting IL‐5 signalling (anti‐IL‐5 or anti‐IL‐5Rα) with placebo on exacerbations, health‐related quality‐of‐life (HRQoL) measures and lung function in adults and children with chronic asthma, and specifically in those with eosinophilic asthma refractory to existing treatments.
cochranelibrary.com